Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Cutaneous a-Synuclein Signatures in Patients with MultipleSystem Atrophy and Parkinson Disease
Neurol 100:e1529-e1539, Gibbons,C.,et al, 2023
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Changing Gears - DBS for Dopaminergic Desensitization in Parkinsons Disease?
Ann Neurol 90:699-710, Weiss, D.,et al, 2021
Beware of Deep Water After Subthalamic Deep Brain Stimulation
Neurol 94:39-41, Waldvogel, D.,et al, 2020
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Vitamin B6 Deficiency Presenting with New-Onset Epilepsy and Status Epilepticus in a Patient with Parkinson Disease
Neurol 94:e2605-e2607, Modica, J.S.,et al, 2020
Deep Brain Stimulation in Early-Stage Parkinson Disease
Neurol 95:e393-e401,e431, Hacker, M.L.,et al, 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinsons Disease
NEJM 383:2501-2513,2582, Martinez-Fernandez, R.,et al, 2020
When to Start Levodopa Therapy for Parkinsons Disease
NEJM 380:389-390, Bressman, S. & Saunders-Pullman, R., 2019
Serum NFL discriminates Parkinson Disease from Atypical Parkinsonisms
Neurol 92:e1479-e1486, Marques, T.M.,et al, 2019
Placebo-Controlled, Randomized, Double-Blind Study of IncobotulinumtoxinA for Sialorrhea
Neurol 92:e1982-e1991, Jost, W.H.,et al, 2019
Suicide and Suicide Attempts after Subthalamic Nucleus Stimulation in Parkinson Disease
Neurol 93:e97-e105, Giannini, G.,et al, 2019
A 58-year-old Man with Hand Tremor and Episodes of Neck Pain
Neurol 93:557-561, Urso, D.,et al, 2019
The Laser Shoes
Neurol 90:e164-e171, Barthel, C.,et al, 2018
The Parkinson Pandemic - A Call to Action
JAMA Neurol 75:9-10, Dorsey, E.R. & Bloem, B.R., 2018
Blood-based NfL - A biomarker for differential diagnosis of parkinsonian disorder
Neurol 88:930-937,922, Hansson, O.,et al, 2017
Viral Hepatitis and Parkinson Disease
Neurol 88:1630-1633, Pakpoor, J.,et al, 2017
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?
AJNR 38:1737-1741, Shams, S.,et al, 2017
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Early Weight Loss in Parkinsonism Predicts Poor Outcomes
Neurol 89:2254-2261, Cumming, K.,et al, 2017
Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients with Medication-Refractory, Tremor-Dominant Parkinson Disease
JAMA Neurol 74:1412-1418, Bond, A.E.,et al, 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Exploring the Association Between Rosacea and Parkinson Disease
JAMA Neurol 73:529-534, Egeberg, A.,et al, 2016
Parkinsonism in a Diabetic Uremic Patient
Neurol 86:e225-e227, Osaki, Y.,et al, 2016
Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease
JAMA Neurol 73:668-674, Martikainen, M.H.,et al, 2016
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Parkinsons Disease Beyond 20 Years
JNNP 86:849-855, Cilia, R.,et al, 2015
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of DIagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality
AJNR 36:2010-2016, Noh, Y.,et al, 2015
Effect of Subthalamic Nucleus Deep Brain Stimulation on Driving in Parkinson Disease
Neurol 82:32-40, Buhmann, C.,et al, 2014
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Long-Term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease Implications for the Future of Cell Therapy
JAMA 311:617-618, Bega, D. & Krainc, D., 2014
Tremor
JAMA 311:948-954, Elias, W.J. & Shah, B.B., 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Parkinson Disease Subtypes
JAMA 71:499-504, Thenganatt, M. & Jankovic, J., 2014
Skin Nerve (-Synuclein Deposits
Neurol 82:1362-1369, Donadio, V.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014